ImmuneOnco doses first patient in Phase II trial of IMM2510-IMM27M combo for first-line advanced liver cancer

• ImmuneOnco dosed the first patient in a Phase II study of IMM2510 with IMM27M as first-line treatment for advanced liver cancer.
• No new study results were presented; the trial will assess whether the regimen can deliver meaningful efficacy with an acceptable safety profile.
• Earlier Phase Ib data were described as encouraging, supporting expansion work in other solid tumors following prior immunotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303249), on August 27, 2026, and is solely responsible for the information contained therein.